Harvard Bioscience Files 8-K on Officer/Director Changes
Ticker: HBIO · Form: 8-K · Filed: Apr 16, 2025 · CIK: 1123494
| Field | Detail |
|---|---|
| Company | Harvard Bioscience Inc (HBIO) |
| Form Type | 8-K |
| Filed Date | Apr 16, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, corporate-governance, filing
TL;DR
Harvard Bioscience is changing up its board and execs, filing an 8-K on it.
AI Summary
Harvard Bioscience, Inc. filed an 8-K on April 16, 2025, reporting events as of April 10, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes financial statements and exhibits.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: medium — Changes in directors and officers can signal internal shifts or strategic realignments that may carry inherent risks.
Key Players & Entities
- HARVARD BIOSCIENCE, INC. (company) — Registrant
- April 10, 2025 (date) — Earliest event reported
- April 16, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- 84 October Hill Road (address) — Principal Executive Offices
- Holliston, MA (location) — Principal Executive Offices
FAQ
What specific officer or director positions were affected by the events reported on April 10, 2025?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' but does not specify names or exact positions within this excerpt.
Are there any details provided regarding the compensatory arrangements for the officers mentioned?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item information, but the specific details of these arrangements are not included in the provided text.
What is the significance of filing under Section 13 or 15(d) of the Securities Exchange Act of 1934?
Filing under Section 13 or 15(d) signifies that Harvard Bioscience, Inc. is a reporting company subject to the requirements of the Securities Exchange Act of 1934.
What is the SIC code for Harvard Bioscience, Inc. and what does it represent?
The SIC code is 3826, which corresponds to 'Laboratory Analytical Instruments'.
When is Harvard Bioscience, Inc.'s fiscal year end?
The fiscal year end for Harvard Bioscience, Inc. is December 31st (1231).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 16, 2025 regarding HARVARD BIOSCIENCE INC (HBIO).